Related references
Note: Only part of the references are listed.Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma
G. Lin et al.
ANNALS OF ONCOLOGY (2020)
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First -Line Crizotinib-Treated ALK-Rearranged NSCLC
Yongchang Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study
Jing Zheng et al.
LUNG CANCER (2020)
Molecular and clinicopathological characteristics ofROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing
Meiying Cui et al.
MOLECULAR ONCOLOGY (2020)
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Yudong Su et al.
TARGETED ONCOLOGY (2019)
CNS metastasis in ROS1 + NSCLC: An urgent call to action, to understand, and to overcome
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2019)
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
Shuguang Xu et al.
BMC CANCER (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
Jing Luo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Ziming Li et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Sehhoon Park et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
Liang Zeng et al.
ONCOTARGETS AND THERAPY (2018)
GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model
D. Torres-Garcia et al.
VACCINE (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2016)
TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling
Viola Weijia Zhu et al.
LUNG CANCER (2016)
Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics
Linn Fagerberg et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
Sai-Hong Ignatius Ou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Share Paper
